This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Applied Genetic Technologies Corp
Sponsor:
Information provided by (Responsible Party):
Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier:
NCT02416622
First received: April 2, 2015
Last updated: June 27, 2017
Last verified: June 2017
  Purpose
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.

Condition Intervention Phase
X-linked Retinoschisis Biological: rAAV2tYF-CB-hRS1 Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis

Resource links provided by NLM:


Further study details as provided by Applied Genetic Technologies Corp:

Primary Outcome Measures:
  • Number of participants experiencing adverse events [ Time Frame: From Day 0 to Month 12 ]

Secondary Outcome Measures:
  • Changes in visual acuity [ Time Frame: From Day 0 to Month 12 ]
  • Changes in schisis cavity size on optical coherence tomography (OCT) [ Time Frame: From Day 0 to Month 12 ]
  • Changes in b-wave amplitude in electroretinogram (ERG) responses [ Time Frame: From Day 0 to Month 12 ]

Estimated Enrollment: 27
Study Start Date: May 2015
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Groups 1A and 1B
Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
Biological: rAAV2tYF-CB-hRS1
adeno-associated virus vector expressing retinoschisin
Experimental: Group 2
Subjects at least 18 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
Biological: rAAV2tYF-CB-hRS1
adeno-associated virus vector expressing retinoschisin
Experimental: Group 3
Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
Biological: rAAV2tYF-CB-hRS1
adeno-associated virus vector expressing retinoschisin
Experimental: Group 4
Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
Biological: rAAV2tYF-CB-hRS1
adeno-associated virus vector expressing retinoschisin

Detailed Description:

This will be a non-randomized, open label, Phase 1/2 dose escalation study.

Up to 27 participants will be enrolled. Each participant will receive the study agent by intravitreal injection in one eye on a single occasion. Enrollment will begin with the lowest dose and will proceed to higher doses only after review of safety data by a Data and Safety Monitoring Committee (DSMC). Participants in the dose escalation phase will be ≥ 18 years of age. After the maximum tolerated dose is identified individuals ≥ 6 years of age will be enrolled.

Safety will be measured by the number and proportion of participants experiencing adverse events and immune response to RS1. Efficacy will be measured by evaluation of changes in visual function and schisis cavity size.

  Eligibility

Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria include:

  1. Retinal disease consistent with a diagnosis of XLRS and documented mutations in the RS1 gene
  2. Male individual at least 18 years of age (dose escalation phase) or at least 6 years of age (maximum tolerated dose phase),
  3. Able to perform tests of visual and retinal function,
  4. Visual acuity specified for each group
  5. Not treated with CAIs currently or within 3 months prior to study enrollment,
  6. Have acceptable laboratory parameters.

Exclusion Criteria include:

  1. Prior receipt of any AAV gene therapy product,
  2. Pre-existing eye conditions that would preclude the planned intravitreal injection or interfere with interpretation of study endpoints or complications of vector administration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02416622

Contacts
Contact: Jill Dolgin, PharmD advocacy@agtc.com

Locations
United States, California
University of California San Francisco, Dept. of Ophthalmology Recruiting
San Francisco, California, United States, 94143
United States, Maryland
The Wilmer Eye Institute, Johns Hopkins Hospital Recruiting
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts Eye and Ear Infirmary Recruiting
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan Kellogg Eye Center Recruiting
Ann Arbor, Michigan, United States, 48105
United States, Oregon
Casey Eye Institute, Oregon Health and Sciences University Recruiting
Portland, Oregon, United States, 97239
United States, Texas
Retina Foundation of the Southwest Recruiting
Dallas, Texas, United States, 75231
Baylor College of Medicine, Alkek Eye Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
Applied Genetic Technologies Corp
Investigators
Study Director: Mike Goldstein, MD Applied Genetics Technologies Corporation
  More Information

Additional Information:
Publications:
Responsible Party: Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier: NCT02416622     History of Changes
Other Study ID Numbers: AGTC-RS1-001
Study First Received: April 2, 2015
Last Updated: June 27, 2017

Keywords provided by Applied Genetic Technologies Corp:
XLRS
maculoschisis
retinal degeneration
RS1
adeno-associated virus
gene therapy
AAV

Additional relevant MeSH terms:
Retinoschisis
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on August 22, 2017